The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Biosimilars-Global Market Insights and Sales Trends 2024

Biosimilars-Global Market Insights and Sales Trends 2024

Publishing Date : Dec, 2023

License Type :
 

Report Code : 1857659

No of Pages : 128

Ask Your Query
Synopsis
A biosimilar is a biologic medical product highly similar to another already approved biological medicine (the 'reference medicine'). Biosimilars are approved according to the same standards of pharmaceutical quality, safety and efficacy that apply to all biological medicines. Biosimilars are officially approved versions of original "innovator" products and can be manufactured when the original product's patent expires. Reference to the innovator product is an integral component of the approval.
The global Biosimilars market size is expected to reach US$ 18790 million by 2029, growing at a CAGR of 18.0% from 2023 to 2029. The market is mainly driven by the significant applications of Biosimilars in various end use industries. The expanding demands from the Oncology, Blood Disorders, Growth Hormonal Deficiency and Chronic and Autoimmune Disorders, are propelling Biosimilars market. Recombinant Non-glycosylated Proteins (Insulin, rHGH, Interferon), one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Recombinant Glycosylated Proteins segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Biosimilars, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Biosimilars market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Biosimilars market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Biosimilars sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Biosimilars covered in this report include Pfizer, Novartis, Biocon, Biogen, Fresenius Kabi AG, Boehringer Ingelheim, Merck KgaA, Mylan and Eli Lilly, etc.
The global Biosimilars market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Pfizer
Novartis
Biocon
Biogen
Fresenius Kabi AG
Boehringer Ingelheim
Merck KgaA
Mylan
Eli Lilly
Teva Pharmaceutical
Dr. Reddy's Laboratories
Amgen
Celltrion
Samsung Biologics
Roche
Probiomed
Apotex
Chong Kun Dang
JCR Pharmaceuticals
Gan & Lee Pharmaceuticals
Gedeon Richter
Biocad
Coherus Bioscience
Stada Arzneimittel AG
Global Biosimilars market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Biosimilars market, Segment by Type:
Recombinant Non-glycosylated Proteins (Insulin, rHGH, Interferon)
Recombinant Glycosylated Proteins
Global Biosimilars market, by Application
Oncology
Blood Disorders
Growth Hormonal Deficiency
Chronic and Autoimmune Disorders
Others
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Biosimilars manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Biosimilars in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Index
1 Biosimilars Market Overview
1.1 Biosimilars Product Overview
1.2 Biosimilars Market Segment by Type
1.2.1 Recombinant Non-glycosylated Proteins (Insulin, rHGH, Interferon)
1.2.2 Recombinant Glycosylated Proteins
1.3 Global Biosimilars Market Size by Type
1.3.1 Global Biosimilars Market Size Overview by Type (2018-2029)
1.3.2 Global Biosimilars Historic Market Size Review by Type (2018-2023)
1.3.3 Global Biosimilars Forecasted Market Size by Type (2024-2029)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Biosimilars Sales Breakdown by Type (2018-2023)
1.4.2 Europe Biosimilars Sales Breakdown by Type (2018-2023)
1.4.3 Asia-Pacific Biosimilars Sales Breakdown by Type (2018-2023)
1.4.4 Latin America Biosimilars Sales Breakdown by Type (2018-2023)
1.4.5 Middle East and Africa Biosimilars Sales Breakdown by Type (2018-2023)
2 Global Biosimilars Market Competition by Company
2.1 Global Top Players by Biosimilars Sales (2018-2023)
2.2 Global Top Players by Biosimilars Revenue (2018-2023)
2.3 Global Top Players by Biosimilars Price (2018-2023)
2.4 Global Top Manufacturers Biosimilars Manufacturing Base Distribution, Sales Area, Product Type
2.5 Biosimilars Market Competitive Situation and Trends
2.5.1 Biosimilars Market Concentration Rate (2018-2023)
2.5.2 Global 5 and 10 Largest Manufacturers by Biosimilars Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Biosimilars as of 2022)
2.7 Date of Key Manufacturers Enter into Biosimilars Market
2.8 Key Manufacturers Biosimilars Product Offered
2.9 Mergers & Acquisitions, Expansion
3 Biosimilars Status and Outlook by Region
3.1 Global Biosimilars Market Size and CAGR by Region: 2018 VS 2022 VS 2029
3.2 Global Biosimilars Historic Market Size by Region
3.2.1 Global Biosimilars Sales in Volume by Region (2018-2023)
3.2.2 Global Biosimilars Sales in Value by Region (2018-2023)
3.2.3 Global Biosimilars Sales (Volume & Value) Price and Gross Margin (2018-2023)
3.3 Global Biosimilars Forecasted Market Size by Region
3.3.1 Global Biosimilars Sales in Volume by Region (2024-2029)
3.3.2 Global Biosimilars Sales in Value by Region (2024-2029)
3.3.3 Global Biosimilars Sales (Volume & Value), Price and Gross Margin (2024-2029)
4 Global Biosimilars by Application
4.1 Biosimilars Market Segment by Application
4.1.1 Oncology
4.1.2 Blood Disorders
4.1.3 Growth Hormonal Deficiency
4.1.4 Chronic and Autoimmune Disorders
4.1.5 Others
4.2 Global Biosimilars Market Size by Application
4.2.1 Global Biosimilars Market Size Overview by Application (2018-2029)
4.2.2 Global Biosimilars Historic Market Size Review by Application (2018-2023)
4.2.3 Global Biosimilars Forecasted Market Size by Application (2024-2029)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America Biosimilars Sales Breakdown by Application (2018-2023)
4.3.2 Europe Biosimilars Sales Breakdown by Application (2018-2023)
4.3.3 Asia-Pacific Biosimilars Sales Breakdown by Application (2018-2023)
4.3.4 Latin America Biosimilars Sales Breakdown by Application (2018-2023)
4.3.5 Middle East and Africa Biosimilars Sales Breakdown by Application (2018-2023)
5 North America Biosimilars by Country
5.1 North America Biosimilars Historic Market Size by Country
5.1.1 North America Biosimilars Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
5.1.2 North America Biosimilars Sales in Volume by Country (2018-2023)
5.1.3 North America Biosimilars Sales in Value by Country (2018-2023)
5.2 North America Biosimilars Forecasted Market Size by Country
5.2.1 North America Biosimilars Sales in Volume by Country (2024-2029)
5.2.2 North America Biosimilars Sales in Value by Country (2024-2029)
6 Europe Biosimilars by Country
6.1 Europe Biosimilars Historic Market Size by Country
6.1.1 Europe Biosimilars Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
6.1.2 Europe Biosimilars Sales in Volume by Country (2018-2023)
6.1.3 Europe Biosimilars Sales in Value by Country (2018-2023)
6.2 Europe Biosimilars Forecasted Market Size by Country
6.2.1 Europe Biosimilars Sales in Volume by Country (2024-2029)
6.2.2 Europe Biosimilars Sales in Value by Country (2024-2029)
7 Asia-Pacific Biosimilars by Region
7.1 Asia-Pacific Biosimilars Historic Market Size by Region
7.1.1 Asia-Pacific Biosimilars Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2029
7.1.2 Asia-Pacific Biosimilars Sales in Volume by Region (2018-2023)
7.1.3 Asia-Pacific Biosimilars Sales in Value by Region (2018-2023)
7.2 Asia-Pacific Biosimilars Forecasted Market Size by Region
7.2.1 Asia-Pacific Biosimilars Sales in Volume by Region (2024-2029)
7.2.2 Asia-Pacific Biosimilars Sales in Value by Region (2024-2029)
8 Latin America Biosimilars by Country
8.1 Latin America Biosimilars Historic Market Size by Country
8.1.1 Latin America Biosimilars Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
8.1.2 Latin America Biosimilars Sales in Volume by Country (2018-2023)
8.1.3 Latin America Biosimilars Sales in Value by Country (2018-2023)
8.2 Latin America Biosimilars Forecasted Market Size by Country
8.2.1 Latin America Biosimilars Sales in Volume by Country (2024-2029)
8.2.2 Latin America Biosimilars Sales in Value by Country (2024-2029)
9 Middle East and Africa Biosimilars by Country
9.1 Middle East and Africa Biosimilars Historic Market Size by Country
9.1.1 Middle East and Africa Biosimilars Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
9.1.2 Middle East and Africa Biosimilars Sales in Volume by Country (2018-2023)
9.1.3 Middle East and Africa Biosimilars Sales in Value by Country (2018-2023)
9.2 Middle East and Africa Biosimilars Forecasted Market Size by Country
9.2.1 Middle East and Africa Biosimilars Sales in Volume by Country (2024-2029)
9.2.2 Middle East and Africa Biosimilars Sales in Value by Country (2024-2029)
10 Company Profiles
10.1 Pfizer
10.1.1 Pfizer Company Information
10.1.2 Pfizer Introduction and Business Overview
10.1.3 Pfizer Biosimilars Sales, Revenue and Gross Margin (2018-2023)
10.1.4 Pfizer Biosimilars Products Offered
10.1.5 Pfizer Recent Development
10.2 Novartis
10.2.1 Novartis Company Information
10.2.2 Novartis Introduction and Business Overview
10.2.3 Novartis Biosimilars Sales, Revenue and Gross Margin (2018-2023)
10.2.4 Novartis Biosimilars Products Offered
10.2.5 Novartis Recent Development
10.3 Biocon
10.3.1 Biocon Company Information
10.3.2 Biocon Introduction and Business Overview
10.3.3 Biocon Biosimilars Sales, Revenue and Gross Margin (2018-2023)
10.3.4 Biocon Biosimilars Products Offered
10.3.5 Biocon Recent Development
10.4 Biogen
10.4.1 Biogen Company Information
10.4.2 Biogen Introduction and Business Overview
10.4.3 Biogen Biosimilars Sales, Revenue and Gross Margin (2018-2023)
10.4.4 Biogen Biosimilars Products Offered
10.4.5 Biogen Recent Development
10.5 Fresenius Kabi AG
10.5.1 Fresenius Kabi AG Company Information
10.5.2 Fresenius Kabi AG Introduction and Business Overview
10.5.3 Fresenius Kabi AG Biosimilars Sales, Revenue and Gross Margin (2018-2023)
10.5.4 Fresenius Kabi AG Biosimilars Products Offered
10.5.5 Fresenius Kabi AG Recent Development
10.6 Boehringer Ingelheim
10.6.1 Boehringer Ingelheim Company Information
10.6.2 Boehringer Ingelheim Introduction and Business Overview
10.6.3 Boehringer Ingelheim Biosimilars Sales, Revenue and Gross Margin (2018-2023)
10.6.4 Boehringer Ingelheim Biosimilars Products Offered
10.6.5 Boehringer Ingelheim Recent Development
10.7 Merck KgaA
10.7.1 Merck KgaA Company Information
10.7.2 Merck KgaA Introduction and Business Overview
10.7.3 Merck KgaA Biosimilars Sales, Revenue and Gross Margin (2018-2023)
10.7.4 Merck KgaA Biosimilars Products Offered
10.7.5 Merck KgaA Recent Development
10.8 Mylan
10.8.1 Mylan Company Information
10.8.2 Mylan Introduction and Business Overview
10.8.3 Mylan Biosimilars Sales, Revenue and Gross Margin (2018-2023)
10.8.4 Mylan Biosimilars Products Offered
10.8.5 Mylan Recent Development
10.9 Eli Lilly
10.9.1 Eli Lilly Company Information
10.9.2 Eli Lilly Introduction and Business Overview
10.9.3 Eli Lilly Biosimilars Sales, Revenue and Gross Margin (2018-2023)
10.9.4 Eli Lilly Biosimilars Products Offered
10.9.5 Eli Lilly Recent Development
10.10 Teva Pharmaceutical
10.10.1 Teva Pharmaceutical Company Information
10.10.2 Teva Pharmaceutical Introduction and Business Overview
10.10.3 Teva Pharmaceutical Biosimilars Sales, Revenue and Gross Margin (2018-2023)
10.10.4 Teva Pharmaceutical Biosimilars Products Offered
10.10.5 Teva Pharmaceutical Recent Development
10.11 Dr. Reddy's Laboratories
10.11.1 Dr. Reddy's Laboratories Company Information
10.11.2 Dr. Reddy's Laboratories Introduction and Business Overview
10.11.3 Dr. Reddy's Laboratories Biosimilars Sales, Revenue and Gross Margin (2018-2023)
10.11.4 Dr. Reddy's Laboratories Biosimilars Products Offered
10.11.5 Dr. Reddy's Laboratories Recent Development
10.12 Amgen
10.12.1 Amgen Company Information
10.12.2 Amgen Introduction and Business Overview
10.12.3 Amgen Biosimilars Sales, Revenue and Gross Margin (2018-2023)
10.12.4 Amgen Biosimilars Products Offered
10.12.5 Amgen Recent Development
10.13 Celltrion
10.13.1 Celltrion Company Information
10.13.2 Celltrion Introduction and Business Overview
10.13.3 Celltrion Biosimilars Sales, Revenue and Gross Margin (2018-2023)
10.13.4 Celltrion Biosimilars Products Offered
10.13.5 Celltrion Recent Development
10.14 Samsung Biologics
10.14.1 Samsung Biologics Company Information
10.14.2 Samsung Biologics Introduction and Business Overview
10.14.3 Samsung Biologics Biosimilars Sales, Revenue and Gross Margin (2018-2023)
10.14.4 Samsung Biologics Biosimilars Products Offered
10.14.5 Samsung Biologics Recent Development
10.15 Roche
10.15.1 Roche Company Information
10.15.2 Roche Introduction and Business Overview
10.15.3 Roche Biosimilars Sales, Revenue and Gross Margin (2018-2023)
10.15.4 Roche Biosimilars Products Offered
10.15.5 Roche Recent Development
10.16 Probiomed
10.16.1 Probiomed Company Information
10.16.2 Probiomed Introduction and Business Overview
10.16.3 Probiomed Biosimilars Sales, Revenue and Gross Margin (2018-2023)
10.16.4 Probiomed Biosimilars Products Offered
10.16.5 Probiomed Recent Development
10.17 Apotex
10.17.1 Apotex Company Information
10.17.2 Apotex Introduction and Business Overview
10.17.3 Apotex Biosimilars Sales, Revenue and Gross Margin (2018-2023)
10.17.4 Apotex Biosimilars Products Offered
10.17.5 Apotex Recent Development
10.18 Chong Kun Dang
10.18.1 Chong Kun Dang Company Information
10.18.2 Chong Kun Dang Introduction and Business Overview
10.18.3 Chong Kun Dang Biosimilars Sales, Revenue and Gross Margin (2018-2023)
10.18.4 Chong Kun Dang Biosimilars Products Offered
10.18.5 Chong Kun Dang Recent Development
10.19 JCR Pharmaceuticals
10.19.1 JCR Pharmaceuticals Company Information
10.19.2 JCR Pharmaceuticals Introduction and Business Overview
10.19.3 JCR Pharmaceuticals Biosimilars Sales, Revenue and Gross Margin (2018-2023)
10.19.4 JCR Pharmaceuticals Biosimilars Products Offered
10.19.5 JCR Pharmaceuticals Recent Development
10.20 Gan & Lee Pharmaceuticals
10.20.1 Gan & Lee Pharmaceuticals Company Information
10.20.2 Gan & Lee Pharmaceuticals Introduction and Business Overview
10.20.3 Gan & Lee Pharmaceuticals Biosimilars Sales, Revenue and Gross Margin (2018-2023)
10.20.4 Gan & Lee Pharmaceuticals Biosimilars Products Offered
10.20.5 Gan & Lee Pharmaceuticals Recent Development
10.21 Gedeon Richter
10.21.1 Gedeon Richter Company Information
10.21.2 Gedeon Richter Introduction and Business Overview
10.21.3 Gedeon Richter Biosimilars Sales, Revenue and Gross Margin (2018-2023)
10.21.4 Gedeon Richter Biosimilars Products Offered
10.21.5 Gedeon Richter Recent Development
10.22 Biocad
10.22.1 Biocad Company Information
10.22.2 Biocad Introduction and Business Overview
10.22.3 Biocad Biosimilars Sales, Revenue and Gross Margin (2018-2023)
10.22.4 Biocad Biosimilars Products Offered
10.22.5 Biocad Recent Development
10.23 Coherus Bioscience
10.23.1 Coherus Bioscience Company Information
10.23.2 Coherus Bioscience Introduction and Business Overview
10.23.3 Coherus Bioscience Biosimilars Sales, Revenue and Gross Margin (2018-2023)
10.23.4 Coherus Bioscience Biosimilars Products Offered
10.23.5 Coherus Bioscience Recent Development
10.24 Stada Arzneimittel AG
10.24.1 Stada Arzneimittel AG Company Information
10.24.2 Stada Arzneimittel AG Introduction and Business Overview
10.24.3 Stada Arzneimittel AG Biosimilars Sales, Revenue and Gross Margin (2018-2023)
10.24.4 Stada Arzneimittel AG Biosimilars Products Offered
10.24.5 Stada Arzneimittel AG Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Biosimilars Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Biosimilars Industrial Chain Analysis
11.4 Biosimilars Market Dynamics
11.4.1 Biosimilars Industry Trends
11.4.2 Biosimilars Market Drivers
11.4.3 Biosimilars Market Challenges
11.4.4 Biosimilars Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Biosimilars Distributors
12.3 Biosimilars Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer

Published By : QY Research

Why ‘The Market Reports’

In Business: Pre Sales Support: Post Sales Support: Turn Around Time: Clients Served: Clients Assisted: Client Types: Payment: Partners with: Number of reports: Custom Research: Report Availability: Report Delivery Format: Security:

Payments Accepted From

Connect with us at

Complete Secure Website

SiteLock